Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute

Pin I. Huang, Shih Chieh Lin, Yi Yen Lee, Donald Ming Tak Ho, Wan Yuo Guo, Kai Ping Chang, Feng Chi Chang, Muh Lii Liang, Hsin Hung Chen, Yu Ming Liu, Sang Hue Yen, Tai-Tong Wong, Yi Wei Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Medulloblastoma (MB) is the most commonly occurring malignant pediatric brain tumor worldwide. However, a recent study found that the treatment outcomes in those with high-risk disease receiving conventional treatment were suboptimal. This study aimed to assess outcomes and treatment strategies for specific histologic subtypes of pediatric MB. Methods: A total of 114 pediatric patients (age < 20 years) diagnosed with MB between March 1998 and August 2011 were retrospectively reviewed; 52 that were treated with surgery followed by adjuvant radiotherapy (RT) and chemotherapy (CHT) were included. Results: The 5-year overall survival (OS) and relapse-free survival (RFS) rates were 73 and 69%, respectively. Median time to relapse was 17 months with a median survival time of 6 months after relapse. Patients of average risk had a better 5-year OS rate compared with high-risk patients (p = 0.027). The 5-year RFS of high-risk patients was lower compared with average risk (p = 0.038). A greater proportion of patients with large cell/anaplastic (LC/A) MB had recurrence than classic MB with 5-year RFS rate of 34 and 76%, respectively (p = 0.001), and OS rate of 56 and 76%, respectively (p = 0.04). Conclusion: High-risk group and histology of LC/A were the most significant factors associated with worse OS and RFS. Patients with LC/A-MB had higher relapse rates and worse survival than those with classic MB. LC/A-MB carries a high risk for recurrence and should be treated with the more aggressive strategies.

Original languageEnglish
Pages (from-to)1285-1294
Number of pages10
JournalChild's Nervous System
Volume33
Issue number8
DOIs
Publication statusPublished - Aug 1 2017
Externally publishedYes

Fingerprint

Medulloblastoma
Recurrence
Survival Rate
Survival
Pediatrics
Adjuvant Radiotherapy
Adjuvant Chemotherapy
Brain Neoplasms
Histology

Keywords

  • Chemotherapy
  • Craniospinal irradiation
  • Craniotomy
  • Large cell/anaplastic medulloblastoma
  • Multidisciplinary treatments
  • Radiotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Huang, P. I., Lin, S. C., Lee, Y. Y., Ho, D. M. T., Guo, W. Y., Chang, K. P., ... Chen, Y. W. (2017). Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute. Child's Nervous System, 33(8), 1285-1294. https://doi.org/10.1007/s00381-017-3435-9

Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute. / Huang, Pin I.; Lin, Shih Chieh; Lee, Yi Yen; Ho, Donald Ming Tak; Guo, Wan Yuo; Chang, Kai Ping; Chang, Feng Chi; Liang, Muh Lii; Chen, Hsin Hung; Liu, Yu Ming; Yen, Sang Hue; Wong, Tai-Tong; Chen, Yi Wei.

In: Child's Nervous System, Vol. 33, No. 8, 01.08.2017, p. 1285-1294.

Research output: Contribution to journalArticle

Huang, PI, Lin, SC, Lee, YY, Ho, DMT, Guo, WY, Chang, KP, Chang, FC, Liang, ML, Chen, HH, Liu, YM, Yen, SH, Wong, T-T & Chen, YW 2017, 'Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute', Child's Nervous System, vol. 33, no. 8, pp. 1285-1294. https://doi.org/10.1007/s00381-017-3435-9
Huang, Pin I. ; Lin, Shih Chieh ; Lee, Yi Yen ; Ho, Donald Ming Tak ; Guo, Wan Yuo ; Chang, Kai Ping ; Chang, Feng Chi ; Liang, Muh Lii ; Chen, Hsin Hung ; Liu, Yu Ming ; Yen, Sang Hue ; Wong, Tai-Tong ; Chen, Yi Wei. / Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute. In: Child's Nervous System. 2017 ; Vol. 33, No. 8. pp. 1285-1294.
@article{7d848a116b8441fda78392171581e95f,
title = "Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute",
abstract = "Purpose: Medulloblastoma (MB) is the most commonly occurring malignant pediatric brain tumor worldwide. However, a recent study found that the treatment outcomes in those with high-risk disease receiving conventional treatment were suboptimal. This study aimed to assess outcomes and treatment strategies for specific histologic subtypes of pediatric MB. Methods: A total of 114 pediatric patients (age < 20 years) diagnosed with MB between March 1998 and August 2011 were retrospectively reviewed; 52 that were treated with surgery followed by adjuvant radiotherapy (RT) and chemotherapy (CHT) were included. Results: The 5-year overall survival (OS) and relapse-free survival (RFS) rates were 73 and 69{\%}, respectively. Median time to relapse was 17 months with a median survival time of 6 months after relapse. Patients of average risk had a better 5-year OS rate compared with high-risk patients (p = 0.027). The 5-year RFS of high-risk patients was lower compared with average risk (p = 0.038). A greater proportion of patients with large cell/anaplastic (LC/A) MB had recurrence than classic MB with 5-year RFS rate of 34 and 76{\%}, respectively (p = 0.001), and OS rate of 56 and 76{\%}, respectively (p = 0.04). Conclusion: High-risk group and histology of LC/A were the most significant factors associated with worse OS and RFS. Patients with LC/A-MB had higher relapse rates and worse survival than those with classic MB. LC/A-MB carries a high risk for recurrence and should be treated with the more aggressive strategies.",
keywords = "Chemotherapy, Craniospinal irradiation, Craniotomy, Large cell/anaplastic medulloblastoma, Multidisciplinary treatments, Radiotherapy",
author = "Huang, {Pin I.} and Lin, {Shih Chieh} and Lee, {Yi Yen} and Ho, {Donald Ming Tak} and Guo, {Wan Yuo} and Chang, {Kai Ping} and Chang, {Feng Chi} and Liang, {Muh Lii} and Chen, {Hsin Hung} and Liu, {Yu Ming} and Yen, {Sang Hue} and Tai-Tong Wong and Chen, {Yi Wei}",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s00381-017-3435-9",
language = "English",
volume = "33",
pages = "1285--1294",
journal = "Child's Nervous System",
issn = "0256-7040",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute

AU - Huang, Pin I.

AU - Lin, Shih Chieh

AU - Lee, Yi Yen

AU - Ho, Donald Ming Tak

AU - Guo, Wan Yuo

AU - Chang, Kai Ping

AU - Chang, Feng Chi

AU - Liang, Muh Lii

AU - Chen, Hsin Hung

AU - Liu, Yu Ming

AU - Yen, Sang Hue

AU - Wong, Tai-Tong

AU - Chen, Yi Wei

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Purpose: Medulloblastoma (MB) is the most commonly occurring malignant pediatric brain tumor worldwide. However, a recent study found that the treatment outcomes in those with high-risk disease receiving conventional treatment were suboptimal. This study aimed to assess outcomes and treatment strategies for specific histologic subtypes of pediatric MB. Methods: A total of 114 pediatric patients (age < 20 years) diagnosed with MB between March 1998 and August 2011 were retrospectively reviewed; 52 that were treated with surgery followed by adjuvant radiotherapy (RT) and chemotherapy (CHT) were included. Results: The 5-year overall survival (OS) and relapse-free survival (RFS) rates were 73 and 69%, respectively. Median time to relapse was 17 months with a median survival time of 6 months after relapse. Patients of average risk had a better 5-year OS rate compared with high-risk patients (p = 0.027). The 5-year RFS of high-risk patients was lower compared with average risk (p = 0.038). A greater proportion of patients with large cell/anaplastic (LC/A) MB had recurrence than classic MB with 5-year RFS rate of 34 and 76%, respectively (p = 0.001), and OS rate of 56 and 76%, respectively (p = 0.04). Conclusion: High-risk group and histology of LC/A were the most significant factors associated with worse OS and RFS. Patients with LC/A-MB had higher relapse rates and worse survival than those with classic MB. LC/A-MB carries a high risk for recurrence and should be treated with the more aggressive strategies.

AB - Purpose: Medulloblastoma (MB) is the most commonly occurring malignant pediatric brain tumor worldwide. However, a recent study found that the treatment outcomes in those with high-risk disease receiving conventional treatment were suboptimal. This study aimed to assess outcomes and treatment strategies for specific histologic subtypes of pediatric MB. Methods: A total of 114 pediatric patients (age < 20 years) diagnosed with MB between March 1998 and August 2011 were retrospectively reviewed; 52 that were treated with surgery followed by adjuvant radiotherapy (RT) and chemotherapy (CHT) were included. Results: The 5-year overall survival (OS) and relapse-free survival (RFS) rates were 73 and 69%, respectively. Median time to relapse was 17 months with a median survival time of 6 months after relapse. Patients of average risk had a better 5-year OS rate compared with high-risk patients (p = 0.027). The 5-year RFS of high-risk patients was lower compared with average risk (p = 0.038). A greater proportion of patients with large cell/anaplastic (LC/A) MB had recurrence than classic MB with 5-year RFS rate of 34 and 76%, respectively (p = 0.001), and OS rate of 56 and 76%, respectively (p = 0.04). Conclusion: High-risk group and histology of LC/A were the most significant factors associated with worse OS and RFS. Patients with LC/A-MB had higher relapse rates and worse survival than those with classic MB. LC/A-MB carries a high risk for recurrence and should be treated with the more aggressive strategies.

KW - Chemotherapy

KW - Craniospinal irradiation

KW - Craniotomy

KW - Large cell/anaplastic medulloblastoma

KW - Multidisciplinary treatments

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85019169612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019169612&partnerID=8YFLogxK

U2 - 10.1007/s00381-017-3435-9

DO - 10.1007/s00381-017-3435-9

M3 - Article

C2 - 28488086

AN - SCOPUS:85019169612

VL - 33

SP - 1285

EP - 1294

JO - Child's Nervous System

JF - Child's Nervous System

SN - 0256-7040

IS - 8

ER -